Table 2

Subgroup analyses of mean (SD) percent change from baseline in sUA level at 4 weeks (ITT population)

Subgroup	Lesinurad 200 mg+allopurinol	Lesinurad 400 mg+allopurinol	Lesinurad 600 mg+allopurinol	Placebo+allopurinol
Baseline estimated CrCl*
≥90 mL/min	n=22	n=19	n=24	n=28
	−15.35 (18.96)†	−19.27 (24.86)†	−28 (14.59)†	2.7 (16.33)
<90 mL/min	n=20	n=21	n=18	n=38
	−15.03 (20.19)†	−24.6 (18.4)†	−32.32 (13.76)†	2.57 (24.27)
Baseline sUA
<8 mg/dL	n=37	n=34	n=32	n=57
	−14.4 (18.1)†	−21.8 (23)†	−27.6 (12.8)†	4.6 (21.9)
8–<10 mg/dL	n=2	n=4	n=7	n=8
	−34.8 (24.78)†	−25.3 (8.8)†	−44.9 (11.59)†	−9.59 (8.1)
≥10 mg/dL	n=1	n=2	n=2	n=1
	−43.5 (NA)	−19.9 (20.3)	−23 (14)	−12.9 (NA)
≥8 mg/dL	n=3	n=6	n=9	n=9
	−37.67 (18.19)†	−23.5 (11.67)†	−40 (14.73)†	−9.91 (7.67)
Initial allopurinol dose
≥300 mg	n=36	n=36	n=31	n=54
	−13.62 (18.77)†	−21.03 (21.83)†	−29.63 (15.06)†	3.43 (22.84)
<300 mg	n=6	n=4	n=11	n=12
	−24.68 (21.63)†	−31.44 (19.2)†	−30.48 (12.24)†	−1.01 (10.21)

*Based on Cockcroft–Gault formula using ideal body weight.
†p<0.05 versus placebo.
CrCl, creatinine clearance; ITT, intention-to-treat; NA, not available; sUA, serum urate.